Wird geladen...
Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration
Rosiglitazone (Rosi) is a drug in the thiazolidinedione class for treatment of Type 2 diabetes mellitus (T2DM), which binds and activates PPARγ nuclear receptor in fat cells, sensitizing them to insulin. Despite proven antidiabetic efficacy, Rosi therapy may be associated with trabecular bone loss a...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2012
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3513662/ https://ncbi.nlm.nih.gov/pubmed/23069375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2012.09.038 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|